In the Zone

$VVUS - Vivus, Inc.

VIVUS, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic drugs for underserved markets worldwide.

The company focuses on developing drug candidates for the treatment of obesity and related morbidities, such as sleep apnea, diabetes, and men's sexual health.

Its lead investigational product in clinical development include QNEXA, which has completed Phase III clinical trials for obesity; and Phase II clinical trials for type 2 diabetes and obstructive sleep apnea.

The company’s drug candidates also comprise Avanafil, an oral PDE5 inhibitor that has completed Phase III trials for erectile dysfunction. VIVUS, Inc. has a licensing agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Avanafil.

The company was founded in 1991 and is headquartered in Mountain View, California.

As this week in the stock market came to a close (VVUS) Vivus, Inc. ended the week trading at $22.13 up $10.14 or 84.57% trading on heavier than average volume of 99.58 million. The average weekly trading volume for (VVUS) Vivus, Inc. is 16.75 billion million. The surge in its stock price was due to FDA approval of its diet pill that will give hope to many persons worldwide who may be overweight and obese.

Please note that this is not a buy recommendation please do your own due diligence or get help from a professional before trading.

By: Marlin Rolle

*** Please have a close look at the charts listed below ****